Fibrocell Science Inc. (FCSC) Financial Statements (2024 and earlier)

Company Profile

Business Address 405 EAGLEVIEW BOULEVARD
EXTON, PA 19341
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2019
MRQ
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 14,43017,41717,51529,26837,49560,033
Cash and cash equivalents 14,43017,41717,51529,26837,49560,033
Receivables    (12)428
Inventory, net of allowances, customer advances and progress billings    482571597
Inventory    482571597
Other undisclosed current assets 1054855131,2561,2781,202
Total current assets: 14,53517,90218,02830,99439,34861,860
Noncurrent Assets
Property, plant and equipment 1,2221,4701,4891,5821,5981,701
Intangible assets, net (including goodwill)    4,1364,6875,238
Intangible assets, net (excluding goodwill)    4,1364,6875,238
Other noncurrent assets 13965 1215
Total noncurrent assets: 1,2231,5091,5545,7186,2867,154
TOTAL ASSETS: 15,75819,41119,58236,71245,63469,014
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1,9222,1221,9912,2782,7993,445
Accounts payable 4528624404991,1242,958
Accrued liabilities 1,4701,2601,5511,7791,675487
Deferred rent credit 150
Deferred revenue and credits  457416148
Due to related parties 1002,30394210,720  
Other undisclosed current liabilities   541,910278 
Total current liabilities: 2,1724,4252,98715,3653,4933,593
Noncurrent Liabilities
Liabilities, other than long-term debt 2,1393,9392,526779724539
Deferred revenue and credits803791   
Deferred rent credit 665
Other liabilities    779724539
Derivative instruments and hedges, liabilities 1,4743,1361,735   
Other undisclosed noncurrent liabilities 1,8902,0406,2086,36511,00815,216
Total noncurrent liabilities: 4,0295,9798,7347,14411,73215,755
Total liabilities: 6,20110,40411,72122,50915,22519,348
Equity
Equity, attributable to parent 9,5579,0077,86114,20330,40949,666
Common stock 102644444140
Additional paid in capital 198,627187,784170,380161,330143,086136,694
Accumulated deficit (189,080)(178,803)(162,563)(147,171)(112,718)(87,068)
Total equity: 9,5579,0077,86114,20330,40949,666
TOTAL LIABILITIES AND EQUITY: 15,75819,41119,58236,71245,63469,014

Income Statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues   355492180200
Revenue, net 337270180200
Cost of revenue   (697)(722)(2,312)(8,052)
Cost of goods and services sold   (696)(426)(2,312)(8,052)
Gross profit:   (342)(230)(2,132)(7,852)
Operating expenses (12,389)(13,261)(22,413)(21,855)(28,447)(23,236)
Other undisclosed operating income (loss)  (5,720)(3,724)(15,322)625585
Operating loss: (12,389)(18,981)(26,479)(37,407)(29,954)(30,503)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
   (7)17368 
Interest and debt expense (771)(828)(228)  2
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes     3,936(1,053)
Loss from continuing operations before equity method investments, income taxes: (13,160)(19,809)(26,714)(37,390)(25,650)(31,554)
Other undisclosed income from continuing operations before income taxes 2,8833,56911,4222,937  
Loss from continuing operations: (10,277)(16,240)(15,292)(34,453)(25,650)(31,554)
Loss before gain (loss) on sale of properties: (10,277)(16,240)(15,292)(34,453)(25,650)(31,554)
Net loss attributable to parent: (10,277)(16,240)(15,292)(34,453)(25,650)(31,554)
Preferred stock dividends and other adjustments (336)(264)    
Other undisclosed net loss available to common stockholders, basic (513)(4,099)    
Net loss available to common stockholders, basic: (11,126)(20,603)(15,292)(34,453)(25,650)(31,554)
Dilutive securities, effect on basic earnings per share  (34)(1,958)1,529  
Other undisclosed net loss available to common stockholders, diluted    (3,058)(2,840)(2,267)
Net loss available to common stockholders, diluted: (11,126)(20,637)(17,250)(35,982)(28,490)(33,821)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (10,277)(16,240)(15,292)(34,453)(25,650)(31,554)
Comprehensive loss, net of tax, attributable to parent: (10,277)(16,240)(15,292)(34,453)(25,650)(31,554)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: